文献速递血脂与心血管预防

环化酶相关蛋白1是PCSK9的结合伴侣并介导LDL受体降解

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
PubMed 文献 · Eur Heart J · 2020-01-01

该研究通过免疫共沉淀、远西方印迹、双分子荧光互补和表面等离子共振证实PCSK9与CAP1直接结合,且PCSK9的CRD结构域与CAP1的SH3BD结构域相互作用。CAP1敲除杂合小鼠肝脏LDLR蛋白水平升高、血浆LDL-C水平降低。机制上PCSK9诱导的LDLR内吞和溶酶体降解由小窝蛋白介导而非网格蛋白,并依赖CAP1与小窝蛋白-1的结合。

要点

  • CAP1是PCSK9的新结合伴侣,介导LDLR的小窝蛋白依赖性内吞和溶酶体降解。
  • CAP1敲除杂合小鼠肝脏LDLR蛋白升高、血浆LDL-C降低。
  • PCSK9 CRD结构域与CAP1 SH3BD结构域结合,人PCSK9功能缺失多态性S668R和G670E影响该结合。

核心结论

  • CAP1是PCSK9的新结合伴侣,是PCSK9介导LDLR小窝蛋白依赖性内吞和溶酶体降解的关键介导因子。

研究设计与样本

  • 基础研究:体外蛋白相互作用实验、siRNA敲低、CAP1敲除小鼠模型。

主要发现

  • 免疫共沉淀、远西方印迹、双分子荧光互补和表面等离子共振证实PCSK9与CAP1直接结合。
  • PCSK9的CRD结构域与CAP1的SH3BD结构域结合;人PCSK9功能缺失多态性S668R和G670E导致与CAP1结合缺陷。
  • siRNA敲低CAP1减少体外PCSK9介导的LDLR降解。
  • CAP1敲除杂合小鼠肝脏LDLR蛋白水平高于对照,血浆LDL-C水平低于对照。
  • PCSK9诱导的LDLR内吞和溶酶体降解由小窝蛋白介导而非网格蛋白,并依赖CAP1与小窝蛋白-1的结合。

临床怎么用

  • CAP1-PCSK9相互作用可能为调节LDLR降解和血浆LDL-C水平提供新靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases. However, the precise mechanism by which PCSK9 regulates the internalization and lysosomal degradation of LDLR is unknown. Recently, we identified adenylyl cyclase-associated protein 1 (CAP1) as a receptor for human resistin whose globular C-terminus is structurally similar to the C-terminal cysteine-rich domain (CRD) of PCSK9. Herein, we investigated the role of CAP1 in PCSK9-mediated lysosomal degradation of LDLR and plasma LDL cholesterol (LDL-C) levels. METHODS AND RESULTS: The direct binding between PCSK9 and CAP1 was confirmed by immunoprecipitation assay, far-western blot, biomolecular fluorescence complementation, and surface plasmon resonance assay. Fine mapping revealed that the CRD of PCSK9 binds with the Src homology 3 binding domain (SH3BD) of CAP1. Two loss-of-function polymorphisms found in human PCSK9 (S668R and G670E in CRD) were attributed to a defective interaction with CAP1. siRNA against CAP1 reduced the PCSK9-mediated degradation of LDLR in vitro. We generated CAP1 knock-out mice and found that the viable heterozygous CAP1 knock-out mice had higher protein levels of LDLR and lower LDL-C levels in the liver and plasma, respectively, than the control mice. Mechanistic analysis revealed that PCSK9-induced endocytosis and lysosomal degradation of LDLR were mediated by caveolin but not by clathrin, and they were dependent on binding between CAP1 and caveolin-1. CONCLUSION: We identified CAP1 as a new binding partner of PCSK9 and a key mediator of caveolae-dependent endocytosis and lysosomal degradation of LDLR.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jang HD, Lee SE, Yang J, et al. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Eur Heart J. 2020. PMID: 31419281. doi:10.1093/eurheartj/ehz566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。